Ascendis Pharma A/S Fundamental Analysis (NASDAQ: ASND)
Ascendis Pharma A/S (NASDAQ: ASND) shows moderate financial fundamentals with a PE ratio of 25.94, profit margin of 58.40%, and ROE of -56.42%. The company generates $0.9B in annual revenue with strong year-over-year growth of 90.22%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -5599.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze ASND's fundamental strength across five key dimensions:
Efficiency Score
ExcellentASND demonstrates superior asset utilization.
Valuation Score
ModerateASND shows balanced valuation metrics.
Growth Score
ExcellentASND delivers strong and consistent growth momentum.
Financial Health Score
WeakASND carries high financial risk with limited liquidity.
Profitability Score
ModerateASND maintains healthy but balanced margins.
Key Financial Metrics
Is ASND Expensive or Cheap?
P/E Ratio
ASND trades at 25.94 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, ASND's PEG of 0.06 indicates potential undervaluation.
Price to Book
The market values Ascendis Pharma A/S at 26.82 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 1040.40 times EBITDA. This signals the market has high growth expectations.
How Well Does ASND Make Money?
Net Profit Margin
For every $100 in sales, Ascendis Pharma A/S keeps $58.40 as profit after all expenses.
Operating Margin
Core operations generate -0.80 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-56.42 in profit for every $100 of shareholder equity.
ROA
Ascendis Pharma A/S generates $25.26 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Ascendis Pharma A/S generates limited operating cash flow of $58.03M, signaling weaker underlying cash strength.
Free Cash Flow
Ascendis Pharma A/S produces free cash flow of $42.40M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.68 in free cash annually.
FCF Yield
ASND converts 0.32% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
25.94
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.06
vs 25 benchmark
P/B Ratio
Price to book value ratio
26.82
vs 25 benchmark
P/S Ratio
Price to sales ratio
15.21
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.84
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.00
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-56.42
vs 25 benchmark
ROA
Return on assets percentage
0.25
vs 25 benchmark
ROCE
Return on capital employed
-0.01
vs 25 benchmark
How ASND Stacks Against Its Sector Peers
| Metric | ASND Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 25.94 | 30.56 | Better (Cheaper) |
| ROE | -5641.90% | 454.00% | Weak |
| Net Margin | 58.40% | -14987.00% (disorted) | Strong |
| Debt/Equity | 1.84 | 0.76 | Weak (High Leverage) |
| Current Ratio | 1.00 | 5.29 | Weak Liquidity |
| ROA | 25.26% | 2930105.00% | Weak |
ASND outperforms its industry in 2 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Ascendis Pharma A/S's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
8208.46%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
56.34%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
115.92%
Industry Style: Defensive, Growth, Innovation
High Growth